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DenosumabAbstract The exponential growth of novel therapies for the treatment of metastatic castra-
tion-resistant prostate cancer (mCRPC) over the last decade has created an acute need for
education and guidance of clinicians regarding optimal strategies for patient management.
A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive
discussion and consensus development, seeking to move the ﬁeld forward and provide guid-
ance and perspectives on optimal selection and sequencing of therapeutic agents and monitor-
ing of response to treatment and disease progression. A total of 110 clinically-relevant
questions were addressed and a modiﬁed Delphi method was utilised to obtain a consensus.
The panel reached a consensus on several important issues, providing recommendations on
appropriate phase III clinical trial end-points and optimal strategies for imaging and monitor-
ing of bone metastases. Guidance regarding selection and sequencing of therapy in patients
with newly diagnosed or progressive mCRPC is emphasised, including the use of novel
bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immu-
notherapy. The impact of drug resistance and prostate-speciﬁc antigen ﬂare on treatment deci-
sions was also addressed. Ultimately, individualised therapy for patients with mCRPC is
dependent on continued reﬁnement of clinical decision-making based on patient and disease
characteristics. This consensus statement offers clinicians expert guidance on the implementa-
tion of recent advances to improve patient outcome, focusing on the future of prostate cancer
care.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Despite continued advances, prostate cancer claims
the lives of over 70,000 men in the European Union
(EU) each year [1]. Although docetaxel has been
established as the standard of care for progressing
patients with metastatic castration-resistant prostate
cancer (mCRPC) who are able to tolerate this agent, it
is now clear that this agent could not be universally used
[2–4]. Intense research and a better understanding of the
pathophysiology of the disease have resulted in the
development of new drugs that are now making their
way into the clinic.
Since 2004, we have learned that the androgen
receptor (AR) could be further manipulated by novel
hormone therapy (i.e. abiraterone acetate and enzaluta-
mide), that the patient immune system could be enlisted
to ﬁght the cancer (sipuleucel-T), that novel chemother-
apy active against docetaxel-resistant cells could be used
(cabazitaxel), and that the bone microenvironment
could more eﬀectively be targeted to delay skeletal com-
plications (i.e. denosumab) or even increase overall sur-
vival (OS) (223RaCl2 — radium 223 dichloride [Ra223])
[5–13]. Clinical trials have compared these new drugs
either to placebo or outdated comparators and there is
no head-to-head comparison between these agents. As
a result, the need for individualised therapy is widely
recognised and treating physicians are left with diﬃcult
choices and few available solid determinants.
Against the backdrop of these novel therapeutic
developments, a panel of European experts convened
with the following objectives:1. To examine appropriate end-points for current and
future clinical trials in mCRPC.
2. To assess the role of imaging in diagnosing metasta-
ses and monitoring response to therapy.
3. To discuss the importance of patient phenotype in
therapeutic decision-making.
4. To review the role of novel bone-targeted radiophar-
maceuticals, chemotherapy, immunotherapy and AR
pathway-targeted agents.
5. To evaluate current opinion regarding the most
appropriate sequencing of available therapies for
mCRPC.
2. Methodology
The European Consensus Panel was held on 7th Sep-
tember 2013 in Nice, France, and consisted of 21 experts
with extensive experience in the ﬁeld of prostate cancer
(Appendix A). The format of the consensus conference
was modelled after that of the very successful St. Gallen
Early Breast Cancer Consensus Conference organised
biannually by Professors H.-J. Senn and A. Goldhirsch
[14]. A modiﬁed Delphi method was used to obtain a
consensus and a consensus threshold of 70% was agreed
upon. Participants considered a series of 110 questions,
completing a baseline questionnaire prior to any discus-
sion. The experts then shared their assessment of topics
by answering speciﬁc questions during the conference.
Guided by the moderator, the panel debated any con-
ﬂicting viewpoints, followed by another opportunity to
vote on the same question. The process continued until
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apparent that a consensus was lacking (Table 1). Not
all questions resulted in a consensus and some experts
chose to abstain due to perceived lack of information
or expertise regarding the topic. To better quantify the
results of this conference, we have used the following
nomenclature throughout this manuscript: strong
consensus (P80% agreement on a choice, with 65%
abstaining), consensus (P70% agreement on a choice,
with 620% abstaining) and no consensus (<70% agree-
ment or >20% abstaining).3. Consensus development and panel discussion
3.1. Clinical trial end-points
Clinical trials and appropriate primary end-points are
critical for moving the ﬁeld of prostate cancer forward.
The panel consensus was that OS and radiologic pro-
gression-free survival (rPFS) were appropriate primary
end-points for phase III clinical trials investigating can-
cer-speciﬁc therapeutic agents for mCRPC. In contrast,
the panel felt that clinical PFS (based on physical exam
and/or pain and/or deterioration of performance status
[PS]), prostate speciﬁc antigen (PSA) progression, occur-
rence of symptomatic skeletal-related events (SREs),
occurrence of pain and quality of life were not appropri-
ate primary end-points for phase III trials, but could
serve as important secondary end-points. Panelists
emphasised that primary end-points will most likely
evolve with the continued emergence of novel therapeu-
tic agents. For bone-targeted therapies, OS is not
required, but the occurrence of SREs may be a suﬃcient
end-point in clinical trials.
Circulating tumour cell (CTC) count is a predictor of
OS in patients with CRPC receiving either chemother-
apy or abiraterone [15–17]. However, the technology
for detection of CTCs requires further ﬁne-tuning to
ensure accuracy [15]. Furthermore, preclinical data sug-
gest that the interaction of CTCs with platelets may pro-
mote evasion of immune surveillance and current CTC
detection methods, suggesting CTC enumeration may
not reﬂect a patient’s true risk for metastatic disease
[18]. Based on currently available data, 86% of the panel
agreed that CTCs are not ready for use as a surrogate
OS marker in clinical trials of CRPC. They also empha-
sised that there are currently no other reliable surrogates
for OS in prostate cancer, including PFS.3.2. Monitoring progression and response
Despite advances in mCRPC, disease diagnosis and
monitoring of progression and response in bone still rely
on 99mTc-polyphosphonate bone scintigraphy and stan-
dard x-rays or computed tomography (CT), even with a
proven poor sensitivity and speciﬁcity. The limitationsof bone scanning were reiterated by the panel, emphasis-
ing that a negative bone scan is not suﬃcient to exclude
the presence of bone metastases, particularly in patients
with bone pain or rapidly rising PSA levels.
The use of advanced imaging modalities, such as pos-
itron emission tomography (PET)/CT and magnetic res-
onance imaging (MRI), has important implications in
treatment decision-making [19]. For patients with bone
pain and equivocal or negative bone scans, the panel
strongly agreed that axial skeleton MRI was a reason-
able and appropriate diagnostic imaging study [20].
Despite initial disagreement regarding the role of plain
x-rays, discussion led to a consensus that x-rays also
have diagnostic value in patients with bone pain and
an equivocal or negative bone scan. Consensus was
reached that [18F]-ﬂuorodeoxyglucose (FDG)–PET/CT
and whole-body MRI are not appropriate in this clinical
setting. The panel identiﬁed axial skeleton MRI as the
most useful imaging tool for assessing response of bone
metastases to therapy over bone scan, whole body MRI
and FDG–PET/CT [21]. The panel stressed that
advanced imaging modalities are not readily accessible
in all areas of the world [19]. Future eﬀorts should focus
on validating newer imaging technologies and making
them aﬀordable and available to all patients.
The panel was initially divided on whether early
imaging was appropriate to detect primary resistance
to novel agents targeting the AR pathway. While early
response assessment gives the opportunity to discon-
tinue ineﬀective therapies, accuracy is highly dependent
on the sensitivity of the imaging method utilised. Fol-
lowing discussion, 81% of the panel members agreed
that early imaging should be performed during therapy
for mCRPC to detect resistance to novel agents target-
ing the AR pathway and 3 months was recommended
as the appropriate minimum time point based on the
imaging modalities currently available. Imaging prior
to 3 months may detect bone ﬂare and should be
avoided.3.3. Therapeutic implications of patient phenotype
The panel agreed unanimously that prostate cancer
demonstrates signiﬁcant heterogeneity between individ-
uals and even within the same patient. In order to better
understand prostate cancer heterogeneity and move the
ﬁeld forward with regard to personalised treatment deci-
sions, the panel reached a consensus that, when possible,
biopsy of metastatic lesions should be considered.
Biopsy of accessible metastatic lesions provides the
opportunity to reassess diﬀerentiation and proliferation
characteristics, conﬁrm that the histology is consistent
with the primary tumour and assess potential tumour
heterogeneity. Discussion amongst the panelists
emphasised that re-biopsy of metastatic sites is impor-
tant, provided that the results can inﬂuence treatment
Table 1
European Consensus Panel voting results. Bolded values indicate the consensus.
Yes No Abstain Consensus
level
Deﬁnition of CRPC
In patients with castrate serum testosterone levels, CRPC can be deﬁned as
Conﬁrmed PSA progression 81% 19% 0% Strong
consensus
Conﬁrmed PSA progression having received combined androgen blockade and after anti-androgen
withdrawal for P4 weeks
57% 38% 5% No
consensus
Conﬁrmed PSA progression after P2 prior hormonal therapies 10% 81% 10% Consensus
End-points for Phase III Clinical Trials
Appropriate primary end-points for phase III clinical trials
OS 100% 0% 0% Strong
consensus
Radiographic progression-free survival 71% 10% 19% Consensus
Clinical progression-free survival 29% 71% 0% Consensus
PSA progression 11% 89% 0% Strong
consensus
Skeletal-related events 29% 71% 0% Consensus
Pain/pain deterioration 10% 90% 0% Strong
consensus
Quality of life deterioration 14% 81% 5% Strong
consensus
Should phase III trial end-points diﬀer depending on the line of therapy? 71% 29% 0% Consensus
Are coprimary end-points appropriate for phase III clinical trials in mCRPC? 76% 24% 0% Consensus
Can CTC count serve as a surrogate for OS in phase III clinical trials of systemic therapy for mCRPC? 10% 86% 5% Strong
consensus
Are there other reliable surrogates for OS? 10% 81% 10% Consensus
Imaging
In the absence of bone pain, is an unequivocally positive or negative bone scan adequate to assess presence
or absence of bone metastases?
38% 62% 0% No
consensus
If bone scan is equivocal or negative despite bone pain, which of the following is reasonable and
appropriate for diagnostic imaging?
Plain x-rays of areas of concern 70% 30% 0% Consensus
Axial skeleton MRI scan 85% 10% 5% Strong
consensus
Whole body MRI scan 29% 71% 0% Consensus
FDG-PET/CT 5% 86% 10% Consensus
Fluoride PET/CT 53% 47% 0% No
consensus
Choline PET/CT 60% 40% 0% No
consensus
Which of the following imaging studies is most useful for assessment of response of bone metastases to therapy?
Tc-99 bone scan 29% 71% 0% Consensus
Whole body MRI 24% 71% 5% Consensus
Axial skeleton MRI 75% 25% 0% Consensus
PET/CT 21% 68% 11% No
consensus
Should early imaging be performed to detect primary resistance to novel agents targeting the AR
pathway?
81% 19% 0% Strong
consensus
Therapeutic Implications of Patient Phenotype
Prostate cancer exhibits histological/genomic heterogeneity
Within the same patient 100% 0% 0% Strong
consensus
Between patients 100% 0% 0% Strong
consensus
Should biopsy of a metastatic site be performed for selected patients with CRPC and accessible lesions? 71% 19% 10% Consensus
Which of the following are reasons for rebiopsy?
To conﬁrm that histology is consistent with prostatic origin 71% 29% 0% Consensus
To reassess diﬀerentiation or proliferation 71% 29% 0% Consensus
To assess potential tumour heterogeneity 84% 11% 5% Strong
consensus
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Table 1 (continued)
Yes No Abstain Consensus
level
How would you deﬁne primary resistance to AR pathway-targeted agents?
Lack of PSA decrease of P50% during therapy 5% 84% 11% Consensus
Lack of PSA decrease of P30% during therapy 5% 90% 5% Strong
consensus
PSA progression within 3 months of therapy initiation 19% 76% 5% Consensus
Radiological progression within 3 months of therapy initiation 76% 14% 10% Consensus
<1 year duration of response to ﬁrst hormonal therapy 5% 90% 5% Strong
consensus
Indicators of increased risk for primary resistance to AR pathway-targeted agents include
High Gleason score grade of primary tumour 53% 42% 5% No consensus
Short duration of response to ﬁrst-line ADT 86% 14% 0% Strong
consensus
Presence of visceral metastases 10% 90% 0% Strong
consensus
Rapid PSA doubling time 15% 80% 5% Strong
consensus
Testosterone level 0% 100% 0% Strong
consensus
Anaemia 0% 95% 5% Strong
consensus
High LDH 10% 90% 0% Strong
consensus
Alkaline phosphatase 0% 100% 0% Strong
consensus
Degree of bone pain 5% 95% 0% Strong
consensus
Decreased performance status 5% 95% 0% Strong
consensus
Preferred ﬁrst-line therapy for a patient with an increased risk for primary resistance to AR-targeted therapy
Taxane 70% 15% 15% Consensus
AR-targeted therapy prior to chemotherapy 10% 81% 10% Consensus
Bone-targeted Therapy
Should every patient with mCRPC and bone metastases (and no contraindications) receive bone-
modifying agents?
24% 76% 0% Consensus
When might radium-223 be used for mCRPC with symptomatic bone metastases?
Postdocetaxel as monotherapy 75% 20% 5% Consensus
Predocetaxel as monotherapy 80% 20% 5% Strong
consensus
Concomitantly with other pre- or post-docetaxel therapies 33% 48% 19% No consensus
Is there a role for radium-223 in asymptomatic mCRPC? 52% 33% 14% No consensus
Assuming EMA approval of radium-223, is there a role for continued use of beta-emitting
radiopharmaceuticals?
48% 38% 14% No consensus
Cross-resistance Between AR Pathway Inhibitors
Is there cross-resistance between approved AR-targeted agents? 90% 5% 5% Strong
consensus
For a patient with disease progression on abiraterone, when could enzalutamide be considered?
If any clinical and/or biochemical response to abiraterone has occurred 29% 67% 5% No consensus
Only if a ‘durable’ response to abiraterone has occurred 24% 76% 0% Consensus
Independent of response to abiraterone 40% 60% 0% No consensus
Should not be considered due to cross-resistance 10% 85% 5% Strong
consensus
For a patient with disease progression on enzalutamide, when could abiraterone be considered?
If any clinical and/or biochemical response to enzalutamide has occurred 24% 76% 0% Consensus
Only if a ‘durable’ response to enzalutamide has occurred 24% 76% 0% Consensus
Independent of response to enzalutamide 48% 52% 0% No consensus
Should not be considered due to cross-resistance 10% 86% 5% Strong
consensus
(continued on next page)
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Table 1 (continued)
Yes No Abstain Consensus
level
Immunotherapy
Is sipuleucel-T a reasonable option for asymptomatic or minimally symptomatic mCRPC? 71% 29% 0% Consensus
How should sipuleucel-T be positioned relative to other approved therapies?
Before docetaxel 81% 5% 14% Consensus
After docetaxel 10% 65% 25% No consensus
Before abiraterone and/or enzalutamide 70% 10% 20% Consensus
After abiraterone and/or enzalutamide, regardless of whether docetaxel is given 10% 67% 24% No consensus
Managing Disease Progression and Sequencing Therapy
mCRPC disease progression can be deﬁned as
Conﬁrmed PSA progression 80% 20% 0% Strong
consensus
Radiologic progression 90% 10% 0% Strong
consensus
Clinical progression 71% 29% 0% Consensus
Pain progression only 10% 90% 0% Strong
consensus
Decreased quality of life 15% 85% 0% Strong
consensus
Which of the following warrants a switch in therapy?
Conﬁrmed PSA progression 14% 81% 5% Strong
consensus
Radiologic progression 81% 14% 5% Strong
consensus
Clinical progression 75% 20% 5% Consensus
Does the sequence of taxane versus AR pathway-targeted therapy ﬁrst change the eﬃcacy of
subsequent therapy?
62% 10% 29% No consensus
Which of the following should be used following disease progression during docetaxel therapy?
AR pathway-targeted agent only 0% 100% 0% Strong
consensus
Cabazitaxel only 10% 90% 0% Strong
consensus
Both an AR pathway-targeted agent and cabazitaxel are reasonable 86% 10% 5% Strong
consensus
Some other approach 5% 35% 60% No consensus
Is there a clinically relevant diﬀerence between primary and acquired resistance to docetaxel? 76% 19% 5% Consensus
For a patient with a partial response to docetaxel and disease progression 66 months following
docetaxel discontinuation, the next line of therapy should be
An AR pathway-targeted agent 95% 5% 0% Strong
consensus
Rechallenge with docetaxel 33% 62% 5% No consensus
Cabazitaxel 100% 0% 0% Strong
consensus
All three options are reasonable 52% 48% 0% No consensus
Some other approach 75% 20% 5% Consensus
For a patient with a partial response to docetaxel and disease progression >6 months following
docetaxel discontinuation, the next line of therapy should be
An AR pathway-targeted agent 100% 0% 0% Strong
consensus
Rechallenge with docetaxel 76% 24% 0% Consensus
Cabazitaxel 100% 0% 0% Strong
consensus
All three options are reasonable 90% 10% 0% Strong
consensus
Some other approach 86% 10% 5% Strong
consensus
When prescribing an AR pathway-targeted agent, which one would you use ﬁrst?
Abiraterone ﬁrst 10% 85% 5% Strong
consensus
Enzalutamide ﬁrst 29% 65% 6% No consensus
It does not matter 71% 19% 10% Consensus
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Table 1 (continued)
Yes No Abstain Consensus
level
Should ongoing LHRH agonist or antagonist therapy be continued when a patient is starting on
abiraterone or enzalutamide?
95% 0% 5% Strong
consensus
In a patient receiving LHRH agonist or antagonist at the time of disease progression on either abiraterone
or enzalutamide, should abiraterone or enzalutamide be discontinued?
85% 0% 15% Strong
consensus
Do you agree that initial PSA rise during docetaxel or cabazitaxel therapy should be ignored? 95% 5% 0% Strong
consensus
Is the occurrence of PSA ﬂare during taxane therapy associated with a similar response compared to
primary responders?
71% 0% 29% No
consensus
Is the occurrence of bone ﬂare associated with an inferior response to therapy compared to a primary
responder without a ﬂare?
0% 76% 24% No
consensus
Abbreviations: ADT, androgen deprivation therapy; AR, androgen receptor; CRPC, castration-resistant prostate cancer; CTC, circulating tumour
cell; EMA, European Medicines Agency; LDH, lactate dehydrogenase; LHRH, luteinizing hormone-releasing hormone; mCRPC, metastatic
CRPC; MRI, magnetic resonance imaging; OS, overall survival; PET/CT, positron emission tomography/computed tomography; PSA, prostate
speciﬁc antigen.
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dard of care since this will require predictive biomarkers
to allow individualised treatment selection [15].
Resistance to treatment is unfortunately common in
mCRPC. The panel consensus was that primary resis-
tance to AR pathway-targeted agents can be deﬁned
as radiologic progression within 3 months following
therapy initiation. Panel members agreed that primary
resistance cannot be suﬃciently deﬁned by a lack of
PSA decrease or PSA progression within 3 months of
therapy initiation. While short response to initial hor-
monal therapy seems to be associated with poor
response to subsequent hormonal therapies, this is not
always an indicator of absolute androgen independence
and does not exclude potential beneﬁt from novel
AR-targeting strategies, such as abiraterone or
enzalutamide.
The panel agreed that short duration of response
(<1 year) to ﬁrst-line androgen deprivation therapy
(ADT) could potentially be used to identify patients
with an increased risk for primary resistance to AR
pathway-targeted agents [22]. The panel felt there is
not suﬃcient evidence to use high Gleason score, the
presence of visceral metastases, rapid PSA doubling
time, testosterone level, anaemia, high lactate dehydro-
genase, alkaline phosphatase, degree of bone pain and
decreased PS as indicators of resistance. While all of
these factors may inﬂuence resistance, none alone
would be suﬃcient to select ﬁrst-line chemotherapy
over AR-targeted therapy. Data from the post-
docetaxel era are currently limited regarding the beneﬁt
of abiraterone or enzalutamide in patients with a high
risk for primary resistance. Thus, clinicians should
consider all patient and disease characteristics when
choosing between chemotherapy and AR-targeted ther-
apies. Given these caveats, the panel agreed that the
preferred ﬁrst-line therapy for patients with mCRPC
and a well-deﬁned risk of primary resistance to AR-tar-
geted therapies would be a taxane rather than an
AR-targeted agent.3.4. Bone-targeted therapies
Denosumab and zoledronic acid are commonly used
to delay and prevent SREs in patients with CRPC and
bone metastases. Despite the signiﬁcant published data
supporting the value of these agents, the panel felt that
the use of bone-targeted therapy should remain an indi-
vidualised treatment decision based on evaluation of the
beneﬁt/risk ratio [11,12,23]. When asked if every patient
with mCRPC and bone metastases should be treated
with a bone-modifying agent, the panel consensus was
‘no’.
There is renewed interest in bone-targeted radiophar-
maceuticals for mCRPC based on recent data demon-
strating an OS advantage for the alpha-emitting agent
Ra223 over placebo in patients with mCRPC and bone
metastases [13]. Consistent with the patient population
from this trial, the panel agreed that Ra223 can be con-
sidered as pre-docetaxel or post-docetaxel therapy in
patients with mCRPC and symptomatic bone metasta-
ses. The panel did not feel there was suﬃcient data to
support its use in patients with asymptomatic bone
metastases. Given the excellent safety proﬁle of Ra223,
there is interest in combination regimens with therapies
such as abiraterone and enzalutamide. However, further
studies are needed before these combinations can be
routinely recommended in clinical practice.
3.5. Cross-resistance between AR pathway inhibitors
Regulatory approval of both abiraterone and enzalu-
tamide raises questions regarding potential cross-resis-
tance and optimal sequencing of AR-targeted therapy
[24]. The panel strongly agreed that at least partial
cross-resistance does exist between approved AR-tar-
geted agents. Small retrospective studies evaluating
patients with progressive CRPC following docetaxel
and enzalutamide demonstrated that subsequent abira-
terone produced few responses of brief duration
[25,26]. Similarly, two retrospective analyses of patients
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docetaxel and abiraterone showed a modest response
rate and evidence of cross-resistance [27,28].
However, cross-resistance was not inevitable and
responses to secondary AR-targeted therapy were
observed [25–28]. Abiraterone and enzalutamide inhibit
persistent AR signalling through diﬀerent mechanisms,
suggesting that patients with resistance to one agent
may still beneﬁt from the other agent. Based on insuﬃ-
cient data to exclude the possibility of crossover
responses, the panel agreed that abiraterone or enzaluta-
mide could be considered for patients who experienced
disease progression while receiving the other AR-tar-
geted agent. However, no consensus was reached
regarding precisely which patients should receive a sec-
ond AR-targeted therapy following progression. Until
conclusive data are available, clinicians need to carefully
consider both patient and disease characteristics when
sequencing these therapies.
3.6. Immunotherapy
Based on current phase III data demonstrating good
tolerability and an OS beneﬁt for sipuleucel-T [9], the
panel agreed it is a reasonable option for patients with
asymptomatic or minimally symptomatic mCRPC.
Importantly, they felt that sipuleucel-T should be con-
sidered prior to docetaxel, abiraterone and enzaluta-
mide, not following these agents. This is in agreement
with the recent EU regulatory approval, which speciﬁed
eligibility only in patients for whom chemotherapy was
not yet clinically indicated [29]. Sipuleucel-T provides
a new treatment option during the time period between
development of castration-resistant disease and becom-
ing a candidate for chemotherapy. Further studies will
be necessary to determine the eﬃcacy, safety and cost-
eﬀectiveness of sipuleucel-T in patients who have
already received abiraterone and/or enzalutamide.
3.7. Managing disease progression and sequencing
therapy
Clear guidelines regarding when to switch therapy
and how to sequence therapy for mCRPC are currently
lacking. It is important to avoid premature treatment
discontinuation and allow adequate time for systemic
therapies to be eﬀective [30]. The panel agreed that
radiologic progression and clinical progression would
warrant a switch in therapy. Importantly, 81% agreed
that it was inappropriate to switch therapy based solely
on conﬁrmed PSA progression. Careful assessment of all
response parameters must be weighed against the spe-
ciﬁc agent’s mode of action in order to determine
whether treatment should be continued or switched [30].
Sequencing therapy is complicated by the potential
for cross-resistance between AR pathway-targetedagents and taxanes [24]. Preclinical studies suggest that
the mechanisms of action for AR-targeted agents and
taxanes overlap regarding interference with AR nuclear
translocation, raising concerns that the action of one of
these agents on AR signalling as ﬁrst-line therapy may
impair the ability of a second-line agent to subsequently
inhibit this pathway [31,32]. This is supported by a ret-
rospective analysis of 35 patients with abiraterone-
pretreated CRPC who subsequently received docetaxel
at progression [33]. Only four patients achieved a
partial radiologic response and the median OS was
12.5 months, compared to a median OS of 18.9 months
for docetaxel administered in a diﬀerent setting but
using the same schedule in patients without prior abira-
terone in the phase III TAX327 trial [2,33]. In a similar
retrospective study of cabazitaxel in patients with pro-
gressive mCRPC following abiraterone and docetaxel,
56% of patients had a PSA decline of P50% and 15%
had a partial response (PR) [34].
While this suggests prior AR pathway-targeted ther-
apy could compromise the eﬃcacy of subsequent taxane
therapy, it is unclear whether the reverse is true. Overall
survival data from the phase III COU-AA-301 and
AFFIRM trials demonstrated sensitivity to abiraterone
and enzalutamide in docetaxel-pretreated mCRPC
[6,8]. However, retrospective studies have shown poor
response to abiraterone and enzalutamide in patients
with disease progression following docetaxel therapy
[22–25,35]. Given the lack of prospective data, the panel
failed to reach a consensus regarding whether the
sequence in which agents are administered changes the
eﬃcacy of subsequent taxane or AR pathway-targeted
therapy, although a majority did feel that drug sequence
may aﬀect response to subsequent therapies.
The panelists also agreed that there is a clinically rel-
evant diﬀerence between primary and acquired resis-
tance to docetaxel. The panel reached a strong
consensus that both AR pathway-targeted agents and
cabazitaxel are reasonable second-line options for
patients experiencing disease progression during doce-
taxel therapy and for those with a PR to docetaxel
who progress 66 months after discontinuing therapy.
There was no consensus on the role for docetaxel rechal-
lenge in patients who progressed within 6 months fol-
lowing completion of initial docetaxel. Conversely, for
patients with disease progression >6 months following
a PR to docetaxel, 90% of the panel felt that all three
options (AR pathway-targeted agents, cabazitaxel and
docetaxel rechallenge) were reasonable. Panel commen-
tary emphasised that while approximately 50% of
patients will respond to docetaxel rechallenge, there
are currently no data to support an OS beneﬁt [36,37].
This should be taken into consideration given the OS
advantage associated with abiraterone, enzalutamide
and cabazitaxel in patients with docetaxel-pretreated
mCRPC [6,8,10]. The panel also agreed that regardless
J.M. Fitzpatrick et al. / European Journal of Cancer 50 (2014) 1617–1627 1625of the duration of response to docetaxel, other
approaches such as Ra223 or enrolment on a clinical
trial could be considered following docetaxel.
When considering an AR pathway-targeted agent for
a patient with disease progression following docetaxel,
the panel agreed that either abiraterone or enzalutamide
could be given ﬁrst as they have not been compared
head-to-head in a clinical trial. There was also a strong
consensus that patients with mCRPC receiving either a
luteinising hormone-releasing hormone (LHRH) agonist
or antagonist should continue on these agents, or have
orchidectomy, when initiating abiraterone or enzaluta-
mide. This is consistent with the current EAU and Euro-
pean Society for Medical Oncology (ESMO) treatment
guidelines [38–40]. Interestingly, 85% of the panel agreed
that patients receiving LHRH agonists or antagonists
with either abiraterone or enzalutamide should discon-
tinue abiraterone or enzalutamide at the time of disease
progression. It was felt that current clinical data are not
suﬃcient to support continuation of these AR pathway-
targeted therapies beyond disease progression, although
ongoing clinical trials will address this issue.
Patients receiving taxanes can exhibit an immediate,
transient rise in PSA levels at therapy initiation
[41,42]. This ﬂare phenomenon precedes actual response
to treatment and can be misinterpreted as therapeutic
failure, leading to premature discontinuation of poten-
tially eﬀective agents. While treatment discontinuation
should be considered for patients with clear signs of
rapid disease progression, 95% of the panel agreed that
initial PSA rise during the ﬁrst 12 weeks of taxane ther-
apy should be ignored. Current data also suggest that
PSA ﬂare has no impact on disease outcome and sur-
vival for patients receiving docetaxel or cabazitaxel
[41]. While the majority of panelists (71%) agreed that
a PSA ﬂare during taxane therapy is associated with
similar response compared to patients who respond with
no PSA ﬂare, 29% abstained, preventing a consensus.4. Conclusions
This consensus statement provides valuable guidance
for clinicians regarding the optimal management of
mCRPC given the current lack of deﬁnitive data and
seeks to move the ﬁeld forward towards more persona-
lised patient care. The treatment of mCRPC is not only
complicated by the sheer number of available therapies,
but the prevalence of resistance to these agents and the
lack of validated predictive markers. The panel identi-
ﬁed considerations for diagnosing and monitoring met-
astatic disease, risk factors for drug resistance,
indicators that warrant a switch in therapy and strate-
gies for treatment selection and sequencing to maximise
the potential for response. Importantly, there was a
clear consensus that novel bone-targeted agents, immu-
notherapy, chemotherapy and AR pathway-targetedagents all play an important role across the mCRPC dis-
ease continuum. The diﬃculty lies in selecting the right
therapy, at the right time and for the right patient. While
this consensus statement provides guidance for making
these diﬃcult treatment decisions, evaluation of all the
factors that contribute to treatment selection is critical
in providing truly personalised care.Conﬂict of interest statement
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